TNSN02018A1 - COMPOSITIONS COMPRENANT UN AGONISTE INVERSE DE GABAa, ET UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN OESTROGENE, UN MODULATEUR SELECTIF DES RECEPTEURS D'OESTROGENE OU DE LA VITAMINE E - Google Patents
COMPOSITIONS COMPRENANT UN AGONISTE INVERSE DE GABAa, ET UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN OESTROGENE, UN MODULATEUR SELECTIF DES RECEPTEURS D'OESTROGENE OU DE LA VITAMINE EInfo
- Publication number
- TNSN02018A1 TNSN02018A1 TNTNSN02018A TNSN02018A TNSN02018A1 TN SN02018 A1 TNSN02018 A1 TN SN02018A1 TN TNSN02018 A TNTNSN02018 A TN TNSN02018A TN SN02018 A TNSN02018 A TN SN02018A TN SN02018 A1 TNSN02018 A1 TN SN02018A1
- Authority
- TN
- Tunisia
- Prior art keywords
- estrogen
- agonist
- vitamin
- inverse
- gabaa
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 102000015694 estrogen receptors Human genes 0.000 title abstract 2
- 108010038795 estrogen receptors Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960002715 nicotine Drugs 0.000 title abstract 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 2
- 239000011782 vitamin Substances 0.000 title abstract 2
- 229940088594 vitamin Drugs 0.000 title abstract 2
- 229930003231 vitamin Natural products 0.000 title abstract 2
- 235000013343 vitamin Nutrition 0.000 title abstract 2
- 150000003722 vitamin derivatives Chemical class 0.000 title abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000019771 cognition Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000004088 simulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
L’INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT DEUX AGENTS ET UN SUPPORT PHARMACEUTIQUEMENT ACCEPTABLE. LE PREMIER AGENT EST UN AGONISTE INVERSE DE GABAa ET LE SECOND AGENT EST UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN AGENT OESTROGENIQUE, UN MODULATEUR SELECTIF DES RECEPTEURS D’OESTROGENE OU LA VITAMINE E. APPLICATION : UTILISATION DE CETTE COMPOSITION POUR LA SIMULATION DE LA COGNITION OU LE TRAITEMENT DE MALADIES COMPORTANT UN DYSFONCTIONNEMENT COGNITIF.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27256601P | 2001-03-01 | 2001-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN02018A1 true TNSN02018A1 (fr) | 2005-12-23 |
Family
ID=23040351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN02018A TNSN02018A1 (fr) | 2001-03-01 | 2002-02-28 | COMPOSITIONS COMPRENANT UN AGONISTE INVERSE DE GABAa, ET UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN OESTROGENE, UN MODULATEUR SELECTIF DES RECEPTEURS D'OESTROGENE OU DE LA VITAMINE E |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20020193360A1 (fr) |
| EP (1) | EP1363606A1 (fr) |
| JP (1) | JP2004527500A (fr) |
| KR (1) | KR20030076717A (fr) |
| CN (1) | CN1494422A (fr) |
| AP (1) | AP2002002465A0 (fr) |
| AR (1) | AR033425A1 (fr) |
| BG (1) | BG108131A (fr) |
| BR (1) | BR0207802A (fr) |
| CA (1) | CA2439581A1 (fr) |
| CR (1) | CR7059A (fr) |
| CZ (1) | CZ20032338A3 (fr) |
| DO (1) | DOP2002000345A (fr) |
| EA (1) | EA200300854A1 (fr) |
| EC (1) | ECSP034759A (fr) |
| EE (1) | EE200300422A (fr) |
| GT (1) | GT200200039A (fr) |
| HU (1) | HUP0303448A3 (fr) |
| IL (1) | IL157465A0 (fr) |
| IS (1) | IS6905A (fr) |
| MA (1) | MA26999A1 (fr) |
| MX (1) | MXPA03007834A (fr) |
| NO (1) | NO20033821L (fr) |
| NZ (1) | NZ527397A (fr) |
| OA (1) | OA12554A (fr) |
| PA (1) | PA8540701A1 (fr) |
| PE (1) | PE20020927A1 (fr) |
| PL (1) | PL364081A1 (fr) |
| SK (1) | SK10752003A3 (fr) |
| TN (1) | TNSN02018A1 (fr) |
| UY (1) | UY27188A1 (fr) |
| WO (1) | WO2002069948A1 (fr) |
| ZA (1) | ZA200306193B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US8030300B2 (en) | 2003-06-10 | 2011-10-04 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP2682481A3 (fr) * | 2005-08-03 | 2014-09-17 | The Johns-Hopkins University | Procédés de caractérisation et de traitement de la déficience cognitive lors du vieillissement et de la maladie |
| EP3050562A1 (fr) | 2006-05-22 | 2016-08-03 | The Board of Trustees of the Leland Stanford Junior University | Traitement pharmacologique de la deficience cognitive utilisant un antagoniste du recepteur gabaa |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| AU2013202426B2 (en) * | 2006-10-16 | 2015-08-06 | Bionomics Limited | Novel anxiolytic compounds |
| AU2007312936B2 (en) * | 2006-10-16 | 2013-09-26 | Bionomics Limited | Novel anxiolytic compounds |
| EP3332797A3 (fr) | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Effets thérapeutiques des bryostatines, bryologues et autres substances apparentées sur les troubles de la mémoire et les lésions cérébrales suite à un traumatisme crânien |
| US8039620B2 (en) * | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
| US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| US10206921B2 (en) * | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| RU2012102052A (ru) * | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
| CN103313712B (zh) | 2010-11-15 | 2016-10-26 | 艾吉因生物股份有限公司 | 用于治疗认知障碍的哒嗪衍生物、组合物和方法 |
| AU2012222874B2 (en) | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
| AU2012222869B2 (en) * | 2011-03-02 | 2015-08-13 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| WO2012151640A1 (fr) | 2011-05-12 | 2012-11-15 | Bionomics Limited | Procédés pour la préparation de naphtyridines |
| US10329301B2 (en) | 2013-12-20 | 2019-06-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
| CN116008442B (zh) * | 2023-03-27 | 2023-06-30 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的合成中间体的杂质检测方法 |
| CN116077459B (zh) * | 2023-04-10 | 2023-07-07 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的胶囊剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL134291A0 (en) * | 1997-08-25 | 2001-04-30 | Neurogen Corp | Substituted 4-oxo-napthyridine-3- carboxamides as gaba brain receptor ligands |
| AU5289600A (en) * | 1999-05-25 | 2000-12-12 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
-
2002
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Ceased
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/fr not_active Ceased
- 2002-02-20 CA CA002439581A patent/CA2439581A1/fr not_active Abandoned
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 PL PL02364081A patent/PL364081A1/xx not_active Application Discontinuation
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 EP EP02700509A patent/EP1363606A1/fr not_active Withdrawn
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
-
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN02018A1 (fr) | COMPOSITIONS COMPRENANT UN AGONISTE INVERSE DE GABAa, ET UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN OESTROGENE, UN MODULATEUR SELECTIF DES RECEPTEURS D'OESTROGENE OU DE LA VITAMINE E | |
| TNSN01068A1 (fr) | Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif | |
| DE69531998D1 (de) | Steroidrezeptor-modulator verbindungen und methoden | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| TNSN98179A1 (fr) | Medicaments | |
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| TNSN98227A1 (fr) | Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant. | |
| WO2000066590A3 (fr) | Composes modulateurs de recepteur de progesterone tetracycliques et procedes | |
| MA29568B1 (fr) | Composes d'azaindazole et methodes d'utilisation desdits composes | |
| MA28289A1 (fr) | Immunoglobulines | |
| DE69937994D1 (de) | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper | |
| TNSN01173A1 (fr) | Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda. | |
| MA28435B1 (fr) | Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 | |
| UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
| MA28111A1 (fr) | Derives des | |
| ATE390917T1 (de) | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten | |
| ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
| NO161557C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-fenyl-2(1h,3h)-indolin-derivater. | |
| EP1334725A3 (fr) | Utilisation d'une composition estroprogestative pour la preparation d'un medicament contraceptif | |
| WO2003105753A3 (fr) | Procedes et compositions pour la greffe de boucles fonctionnelles dans une proteine | |
| WO2003104253A3 (fr) | Estratrienes 9-alpha substitues servant d'oestrogenes selectivement actifs | |
| MXPA04000023A (es) | Derivados de acido cicloalquilpirrol-3-carboxilico y derivados de acido heterocicloalquilpirrol-3-carboxilico como ligandos de receptor gabaa. | |
| TNSN02003A1 (fr) | Association d'un antagoniste des recepteurs d'histamine h1 et d'un antagoniste selectif des recepteurs d'histamine h4, et composition la contenant. | |
| TNSN99118A1 (fr) | Associations therapeutiques pour le traitement de maladies osseuses, et procede pour leur preparation | |
| EP1440080A4 (fr) | Methodes et compositions servant au diagnostic et au traitement de troubles de la proliferation cellulaire impliquant le 20750 |